Jacobs Levy Equity Management

Jacobs Levy Equity Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-62,225	Closed	-$732K	–	1052
2019 Q2	$732K	Sell	62,225 -23,400	-27%	-$283K	0.01%	688
2019 Q1	$1.17M	Buy	85,625 +40,100	+88%	+$520K	0.02%	626
2018 Q4	$467K	Buy	45,525 +20,900	+85%	+$268K	0.01%	743
2018 Q3	$410K	Buy	24,625 +10,925	+80%	+$197K	0.01%	818
2018 Q2	$216K	Buy	+13,700	New	+$208K	﹤0.01%	942
2018 Q1	–	Sell	-33,080	Closed	-$379K	–	1110
2017 Q4	$379K	Buy	+33,080	New	+$369K	0.01%	802

Other funds holding ALDR

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return